Literature DB >> 21736079

Glioblastoma: Part I. Current state of affairs.

Michael E Salacz1, Kenneth R Watson, David A Schomas.   

Abstract

Although uncommon, "brain cancer" is one of the most feared diseases that afflict human beings. While still regarded as one of the most deadly forms of primary brain neoplasm, recent advances in the treatment of glioblastoma (GBM) have offered new hope for patients, families, and clinicians. In the first part of this two-part review, we will focus on the multidisciplinary advances that have established the current treatment approach in the management of GBM. In the second part of this review, ongoing research will be presented including current clinical trials as well as some of the newer technologies that are forming the promise of the future.

Entities:  

Mesh:

Year:  2011        PMID: 21736079      PMCID: PMC6188294     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  32 in total

Review 1.  Improvements in brain tumor surgery: the modern history of awake craniotomies.

Authors:  Ketan R Bulsara; Joel Johnson; Alan T Villavicencio
Journal:  Neurosurg Focus       Date:  2005-04-15       Impact factor: 4.047

Review 2.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

3.  Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

Authors:  René-Olivier Mirimanoff; Thierry Gorlia; Warren Mason; Martin J Van den Bent; Rolf-Dieter Kortmann; Barbara Fisher; Michele Reni; Alba A Brandes; Jüergen Curschmann; Salvador Villa; Gregory Cairncross; Anouk Allgeier; Denis Lacombe; Roger Stupp
Journal:  J Clin Oncol       Date:  2006-06-01       Impact factor: 44.544

4.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

5.  Clinical features of primary brain tumours: a case-control study using electronic primary care records.

Authors:  William Hamilton; David Kernick
Journal:  Br J Gen Pract       Date:  2007-09       Impact factor: 5.386

6.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506

7.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

Authors:  Alba A Brandes; Enrico Franceschi; Alicia Tosoni; Valeria Blatt; Annalisa Pession; Giovanni Tallini; Roberta Bertorelle; Stefania Bartolini; Fabio Calbucci; Alvaro Andreoli; Giampiero Frezza; Marco Leonardi; Federica Spagnolli; Mario Ermani
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

8.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank J Attenello; Khoi Than; Alessandro Olivi; Jon D Weingart; Henry Brem; Alf Redo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2009-01       Impact factor: 5.115

Review 9.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Authors:  Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

10.  Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.

Authors:  Doo-Sik Kong; Jung-Il Lee; Jong Hyun Kim; Sung Tae Kim; Won Seog Kim; Yeon-Lim Suh; Seung Myung Dong; Do-Hyun Nam
Journal:  Neuro Oncol       Date:  2010-01-11       Impact factor: 12.300

View more
  6 in total

1.  Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells.

Authors:  Prateek Bhatia; Michel Bernier; Mitesh Sanghvi; Ruin Moaddel; Roland Schwarting; Anuradha Ramamoorthy; Irving W Wainer
Journal:  Xenobiotica       Date:  2012-03-08       Impact factor: 1.908

Review 2.  Glioblastoma: Overview of Disease and Treatment.

Authors:  Mary Elizabeth Davis
Journal:  Clin J Oncol Nurs       Date:  2016-10-01       Impact factor: 1.027

3.  Nanoparticles of carbon allotropes inhibit glioblastoma multiforme angiogenesis in ovo.

Authors:  Marta Grodzik; Ewa Sawosz; Mateusz Wierzbicki; Piotr Orlowski; Anna Hotowy; Tomasz Niemiec; Maciej Szmidt; Katarzyna Mitura; André Chwalibog
Journal:  Int J Nanomedicine       Date:  2011-11-25

4.  Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ.

Authors:  Xia Qiu; Jianguo Jiao; Yidong Li; Tian Tian
Journal:  Oncotarget       Date:  2016-12-27

5.  BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.

Authors:  L Persano; F Pistollato; E Rampazzo; A Della Puppa; S Abbadi; C Frasson; F Volpin; S Indraccolo; R Scienza; G Basso
Journal:  Cell Death Dis       Date:  2012-10-18       Impact factor: 8.469

6.  Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.

Authors:  Pengfei Jiang; Rajesh Mukthavaram; Rajesh Mukthavavam; Ying Chao; Ila Sri Bharati; Valentina Fogal; Sandra Pastorino; Xiuli Cong; Natsuko Nomura; Matt Gallagher; Taher Abbasi; Shireen Vali; Sandeep C Pingle; Milan Makale; Santosh Kesari
Journal:  J Transl Med       Date:  2014-01-17       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.